Letrozole for Ovulation Induction: Key Prescribing Considerations

Patient Selection and Contraindications

Premenopausal women with functioning ovaries should NOT receive letrozole for breast cancer treatment, as aromatase inhibitors alone are ineffective and contraindicated in this population, according to the American Society of Clinical Oncology 1

Continue letrozole treatment for 3-6 cycles before considering alternative interventions, as recommended by the American College of Obstetricians and Gynecologists 2
If pregnancy is not achieved after 3-6 cycles, add intrauterine insemination, as suggested by the American Society for Reproductive Medicine 2
Refer for IVF if letrozole treatment is unsuccessful after an appropriate trial, as recommended by the American College of Obstetricians and Gynecologists 2

Regular ultrasound monitoring is essential to ensure appropriate follicular development and reduce multiple pregnancy risk, according to the American College of Obstetricians and Gynecologists 2
Monitor follicle size and number during each treatment cycle, as recommended by the European Society of Human Reproduction and Embryology 3
Cycles of 38-40 days do not require intervention, but concerning signs such as bleeding saturating a large pad hourly for ≥4 hours, hemodynamic instability, or abrupt change to heavy bleeding require evaluation, as suggested by the American College of Obstetricians and Gynecologists 4

Letrozole can be used during ovarian stimulation without reducing mature oocyte yield or fertilization capacity, according to the American Society for Reproductive Medicine 3
Letrozole may be beneficial for patients with antiphospholipid antibodies or thrombophilia due to lower peak estrogen levels, as recommended by the American College of Chest Physicians 5

Letrozole maintains estrogen levels near physiologic ranges, reducing OHSS risk, according to the American Society for Reproductive Medicine 4
Letrozole maintains adequate endometrial development even at high doses, as recommended by the European Society of Human Reproduction and Embryology 5

Do not use aromatase inhibitors alone in premenopausal women for breast cancer treatment, as they are ineffective without ovarian suppression, according to the American Society of Clinical Oncology 1
Do not skip ultrasound monitoring, as it is essential for preventing multiple pregnancies and confirming appropriate follicular response, as recommended by the American College of Obstetricians and Gynecologists 2

The American Society of Clinical Oncology (ASCO) and NCCN guidelines identify chemotherapy agents, pelvic radiation > 6 Gy, and myeloablative conditioning as high‑risk factors for treatment‑related amenorrhea and early menopause, while short‑term letrozole used for ovulation induction is not included among these risks. 6
The European Society for Medical Oncology (ESMO) fertility‑preservation guideline does not place letrozole in any risk category (high, intermediate, low, or unknown) for treatment‑related amenorrhea, indicating it is not considered gonadotoxic in infertility protocols. 6

In breast‑cancer adjuvant therapy, letrozole is administered continuously on a daily basis for ≥ 5 years to postmenopausal women who have already completed menopause; this prolonged exposure differs fundamentally from the 5‑day, 2.5‑7.5 mg cycles (typically 3‑6 cycles) used for ovulation induction in premenopausal patients. 7, 8

Data reported in Annals of Oncology show that letrozole does not impair endometrial development, mature‑oocyte yield, or fertilization capacity during infertility treatment, confirming that ovarian function remains intact. 9

The NCCN (2009) emphasizes that the short‑term, cyclical letrozole exposure employed in fertility treatment is not associated with accelerated ovarian aging, contrasting with the prolonged hormonal therapy used in oncology settings. 7, 8